Around the world, Pulitzer Center grantees are reporting on misinformation related to science, climate change, elections, health issues, and fossil fuels. We believe the best way to counter this ...

Adam Coy, who is white, faces life in prison for fatally shooting Andre Hill, 47, in December 2020. Mr Hill had been carrying a mobile phone and keys when Coy shot him four times. Coy, 48 ...

MIAMI GARDENS — There’s a tactic defenses are using to slow Dolphins wide receivers Tyreek Hill and Jaylen Waddle this season, and something that’s almost certain to be used by Buffalo on ...

(AP Photo/Peter Morgan) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] NEW YORK (AP) — U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...

Eli Lilly on Wednesday fell short of profit and revenue expectations for the third quarter, weighed down by disappointing sales of its blockbuster weight loss drug Zepbound and diabetes treatment ...

Copyright 2024 The Associated Press. All Rights Reserved. FILE - This April 26, 2017 file photo shows the Eli Lilly & Co. corporate headquarters in Indianapolis. (AP ...

AJ Mast / Bloomberg via Getty Images Eli Lilly (LLY) shares tumbled 12% at the opening bell Wednesday after its third-quarter results fell well short of analysts' estimates and it lowered its full ...

Drug maker Eli Lilly’s share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare ...

Eli Lilly reported Q3 revenue and earnings that fell short of analysts' expectations. Mounjaro and Zepbound faced challenges as U.S. wholesalers reduced inventories of the drugs. The bull case for ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...